<DOC>
	<DOCNO>NCT01110291</DOCNO>
	<brief_summary>Twenty patient verified high risk breast cancer include study . Patients receive three cycle docetaxel follow three cycle CEF adjuvant treatment . The phenotype CYP3A genotype CYP3A5 MDR1 assess . Also effect docetaxel activity CYP3A measure peroral midazolam . Primary Object : The primary object study define , possible predict clearance and/ toxicity docetaxel assess - activity CYP3A4 midazolam test ( CYP3A4 phenotype ) - CYP3A5 genotype - MDR1 genotype Secondary object : The secondary object study define whether treatment docetaxel alters activity CYP3A4 enzyme previously untreated breast cancer patient .</brief_summary>
	<brief_title>Study Usefulness Genotyping Predict Docetaxel Exposure Adverse Events</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subjects may include study meet follow criterion : 1 . The patient receive information purpose study mean treatment , give verbal write consent participate study . The patient accessible treatment followup . 2 . Histologically verified diagnosis breast cancer 3 . High risk recurrence ( node positive node negative T2 histological grade 2 3 , Pgr negative ) 4 . No metastasis 5 . Females , age = &lt; 60 6 . No concomitant regular medication either substrate , inducer inhibitor CYP3A4 Subjects exclude study follow reason : 1 . Poor performance status , &gt; =2 accord WHO 2 . Inadequate bone marrow reserve define : hemoglobin &lt; 100 g/L leukocyte &lt; 3.0 x 10E9/L neutrophile &lt; 1.5 x 10E9/L plateless &lt; 120 x 10E9/L 3 . Inadequate liver function define : ALAT &gt; 1.5 x unit normal level elevate bilirubin ( unless verify GilbertÂ´s syndrome ) alkaline phosphatase &gt; 2.5 x unit normal level 4 . History concomitant serious physical psychiatric disease , make regular cytotoxic treatment impossible 5. cardiac insufficience ; severe arrhythmia ; severe hypertension ; cardiac infarction within one year active cardiac disease 6. pregnant lactate patient 7. abuse alcohol narcotic substance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>docetaxel toxicity</keyword>
	<keyword>CYP3A activity</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>MDR1</keyword>
	<keyword>peroral midazolam</keyword>
</DOC>